N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide
In Stock•Starting at $17 for 1 mg•Purity ≥ 97%
| CAS No. | 345627-80-7 |
|---|---|
| MDL No. | MFCD09833875 |
| MF | C17H24N4O2S2 |
| MW | 380.50 |
| InChI Key | OUSFTKFNBAZUKL-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| 1 mg | 99% | $17 | In Stock | |
| 5 mg | 99% | $29 | In Stock | |
| 10 mg | 99% | $47 | In Stock | |
| 25 mg | 98% | $86 | In Stock |
Product Information
N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide is a secondary carboxamide formed by the condensation of piperidine-4-carboxylic acid's carboxy group with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7, and CDK9 kinases, exhibiting anti-cancer properties, apoptosis induction, antineoplastic activity, EC 2.7.11.22 (cyclin-dependent kinase) inhibition, and angiogenesis inhibition. It belongs to piperidinecarboxamides, 1,3-oxazoles, 1,3-thiazoles, organic sulfides, and secondary carboxamides.
| CAS No. | 345627-80-7 |
|---|---|
| Product Name | N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide |
Biological Targets
CDK2·CDK7·CDK9
Associated Conditions
multiple myeloma·cancer·neoplasm·chronic lymphocytic leukemia·Mantle cell lymphoma
* The information provided here is compiled from public sources and is for reference only.
